Haita Makanji
About Haita Makanji
Haita Makanji serves as the Vice President of Specialty Clinical Strategy and Innovation at Magellan Rx Management, where she has worked since 2014. She has played a significant role in advancing specialty clinical strategies and enhancing patient care.
Work at Magellan Rx Management
Haita Makanji has been with Magellan Rx Management since 2014, initially serving as Vice President of Clinical Specialty Solutions. In 2019, she transitioned to the role of Vice President, Specialty Clinical Strategy and Innovation. During her tenure, she has played a significant role in driving innovation within the specialty clinical strategy sector. Makanji has contributed to the development of strategic initiatives aimed at enhancing patient care and optimizing clinical outcomes. She was also instrumental in the transition and integration process following Magellan Rx Management's acquisition by Prime Therapeutics.
Previous Experience in Clinical Specialty Solutions
Before joining Magellan Rx Management, Haita Makanji worked at CDMI Health as Manager of Clinical Specialty Solutions from 2012 to 2014. In this role, she focused on clinical specialty services and developed strategies to improve patient outcomes. Prior to her position at CDMI Health, she served as a Staff Pharmacist at Walgreens for six months in 2011. This experience provided her with a solid foundation in pharmacy practice and patient care.
Education and Expertise
Haita Makanji earned her Doctor of Pharmacy (PharmD) degree from the Massachusetts College of Pharmacy and Health Sciences, completing her studies from 2007 to 2011. Prior to that, she attended the University of Connecticut from 2004 to 2007. Her educational background has equipped her with extensive knowledge in pharmacy and clinical practice, which she applies in her current role at Magellan Rx Management.
Professional Contributions
In her role at Magellan Rx Management, Haita Makanji has been involved in various initiatives that aim to enhance patient care and clinical outcomes. Her leadership in specialty clinical strategy has led to the implementation of innovative solutions that address the complexities of specialty medications. Makanji's contributions reflect her commitment to improving healthcare delivery and patient support.